Biologica Raises $7M to Launch Hormone-Stage Women's Supplements

The women’s supplement market is segmenting again. Biologica, launched in April 2026, took the segmentation one step further. Instead of treating “women” as a single category, the brand splits into three hormonal stages: Primary (ages 18-45), Midlife (40-55), and Postmenopause (50+), each with a distinct formula. Joey Zwillinger, co-founder of Allbirds, and his wife Liz Zwillinger raised $7 million in seed funding to launch.

Why they started

Liz Zwillinger described the spark in an interview: “I found myself one day in my kitchen mixing seven different pills, four different powders, and I said, ‘This shouldn’t be this hard.’” The more the supplement market fragments, the heavier the burden on consumers to assemble their own stack, a paradox she experienced firsthand. Before launch, Biologica conducted a 1,000-woman study and nationwide focus groups to map nutrient gaps and stage-specific priorities for American women.

7-10 pills compressed into one sachet

Each daily serving comes in a single sachet, equivalent to 7-10 conventional pills or capsules. All three lines are priced at $79 per month, with subscription discounts available. The sachet format targets consumers who dislike pills and frequent travelers, both groups that show up consistently in supplement compliance studies.

The anchor: 28mg of saffron

Saffron extract at 28mg is shared across all three lines. Saffron has documented effects on menopausal mood, hot flashes, and PMS, with clinical trials standardizing around 28-30mg per day. Comparative trials against SSRIs reported similar effect sizes for mild-to-moderate depression, though saffron is not pharmaceutical-grade in intensity. As one of the most expensive spice extracts, 28mg accounts for a notable fraction of unit cost.

The other anchor is the calcium, vitamin D, and vitamin K2 trio. Including K2 signals awareness of the “calcium paradox,” in which isolated calcium supplementation can raise bone density while increasing arterial calcification risk. Pairing calcium with K2 has become standard in newer protocols as data on the paradox accumulated.

How the stages differ

The three formulas share the anchor and adjust priority nutrients per stage.

• Primary (18-45): iron, folate, magnesium emphasis. Reproductive-age nutrient gap support.
• Midlife (40-55): saffron, inositol, maca, and other hormone-modulating compounds amplified. Perimenopause-focused.
• Postmenopause (50+): calcium, vitamin D and K2 amplified. Bone density and cardiovascular weighting.

Why this matters

The launch reflects a market shift from “women’s supplements” as a single category toward stage-segmented formulations. NOW Foods, Meno, Peri, and similar brands have been expanding stage-specific lines simultaneously. Clinical nutrition research has been generating 1,000-to-2,000-woman studies stratified by hormonal stage, replacing pooled-average data with stage-specific findings.

What consumers should check

$79 per month is not negligible. Buying the same nutrients as individual tablets generally runs $30-50 per month. Biologica’s value lies in formulation and convenience. If your stage doesn’t actually need saffron, the premium line offers limited benefit. If you already take a multivitamin, omega-3, or vitamin D, audit overlap before adding a sachet. A “life-stage” label is not automatically the right prescription for your body.

Where this leads

If women’s supplements are now segmenting by stage, the next frontier is data-driven personalization based on hormonal testing. As DUTCH hormone panels, thyroid panels, and serum nutrient testing become more accessible, the dominant model could shift from stage labels to results-based custom protocols. Biologica is positioning itself as the cleanest standardized prescription before that personalization wave fully arrives.